• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

    2/14/24 4:23:00 PM ET
    $KOD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KOD alert in real time by email
    SC 13G/A 1 d706731dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 5)*

     

     

    Kodiak Sciences Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    50015M109

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-l(b)

    ☐ Rule 13d-l(c)

    ☒ Rule 13d-l(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     


    SCHEDULE 13G

     

    CUSIP No. 50015M109       Page 2 of 5 Pages

     

     1.   

     Names of Reporting Persons.

     

     D. Victor Perlroth, M.D.

     2.  

     Check the Appropriate Box if a Member of a Group (See Instructions)

     (a) ☐  (b) ☐

     

     3.  

     SEC Use Only

     

     4.  

     Citizenship or Place of Organization

     

     United States of America

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

     Sole Voting Power

     

     5,758,427 shares1

       6.   

     Shared Voting Power

     

     N/A

       7.   

     Sole Dispositive Power

     

     5,231,427 shares2

       8.   

     Shared Dispositive Power

     

     N/A

     9.   

     Aggregate Amount Beneficially Owned by Each Reporting Person

     

     5,758,427

    10.  

     Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

     ☐

    11.  

     Percent of Class Represented by Amount in Row (9)

     

     10.4%3

    12.  

     Type of Reporting Person (See Instructions)

     

     IN

     

     

    1 

    Includes (a) 2,108,038 shares held directly by Dr. Perlroth, (b) 3,063,389 shares of common stock that Dr. Perlroth has the right to acquire from the Issuer immediately or within sixty days of December 31, 2023 pursuant to the exercise of option awards, of which 566,173 are unvested, early exercisable and subject to an Issuer right of repurchase as of February 29, 2024, (c) 60,000 shares held by the Perlroth Family Foundation U/A DTD 12/27/2006 for which Dr. Perlroth is a trustee, and (d) 527,000 shares as to which Dr. Perlroth exercises sole voting authority pursuant to a voting agreement and proxy.

    2 

    Includes (a) 2,108,038 shares held directly by Dr. Perlroth, (b) 3,063,389 shares of common stock that Dr. Perlroth has the right to acquire from the Issuer immediately or within sixty days of December 31, 2023 pursuant to the exercise of option awards, of which 566,173 are unvested, early exercisable and subject to an Issuer right of repurchase as of February 29, 2024, and (c) 60,000 shares held by the Perlroth Family Foundation U/A DTD 12/27/2006 for which Dr. Perlroth is a trustee.

    3 

    Based on 52,508,602 shares of common stock outstanding as of December 31, 2023.


    SCHEDULE 13G

     

    CUSIP No. 50015M109       Page 3 of 5 Pages

     

    Item 1.

     

      (a)

    Name of Issuer:

    Kodiak Sciences Inc. (the “Issuer”)

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    1200 Page Mill Road

    Palo Alto, CA 94304

    Item 2.

     

      (a)

    Name of Person Filing:

    D. Victor Perlroth, M.D.

     

      (b)

    Address of Principal Business Office or, if none, Residence:

    The address for the Reporting Person is:

    c/o Kodiak Sciences Inc.

    1200 Page Mill Road

    Palo Alto, CA 94304

     

      (c)

    Citizenship:

    Dr. D. Victor Perlroth is a United States citizen.

     

      (d)

    Title of Class of Securities:

    Common Stock, $0.0001 par value per share

     

      (e)

    CUSIP Number:

    50015M109

    Item 3. If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)    ☐    An investment advisor in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)    ☐    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
    (h)    ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)    ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)    ☐    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J); or
    (k)    ☐    Group, in accordance with § 240.13d-1(b)(1)(ii)(K).


    SCHEDULE 13G

     

    CUSIP No. 50015M109       Page 4 of 5 Pages

     

    Item 4. Ownership.

    The following information with respect to the ownership of the Common Stock of the Issuer by the Reporting Person is provided as of December 31, 2023:

     

      (a)

    Amount beneficially owned

    See Row 9 of cover page.

     

      (b)

    Percent of Class:

    See Row 11 of cover page.

     

      (c)

    Number of shares as to which such person has:

     

    (i) Sole power to vote or to direct the vote    See Row 5 of cover page.
    (ii) Shared power to vote or to direct the vote    See Row 6 of cover page.
    (iii) Sole power to dispose or to direct the disposition of    See Row 7 of cover page.
    (iv) Shared power to dispose or to direct the disposition of    See Row 8 of cover page.

    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

    Item 8. Identification and Classification of Members of the Group.

    Not applicable.

    Item 9. Notice of Dissolution of Group.

    Not applicable.

    Item 10. Certifications.

    Not applicable.


    SCHEDULE 13G

     

    CUSIP No. 50015M109       Page 5 of 5 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

          D. Victor Perlroth, M.D.
    Date: February 14, 2024      

    /s/ D. Victor Perlroth

    Get the next $KOD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KOD

    DatePrice TargetRatingAnalyst
    12/9/2024$20.00Hold → Buy
    Jefferies
    9/5/2024$3.00Neutral
    H.C. Wainwright
    12/11/2023$2.00Sell
    Goldman
    11/17/2023$7.00 → $12.00Equal Weight → Overweight
    CapitalOne
    7/27/2023$15.00 → $4.00Buy → Neutral
    UBS
    7/25/2023Buy → Neutral
    Chardan Capital Markets
    7/25/2023Neutral → Underweight
    JP Morgan
    7/24/2023Buy → Hold
    Jefferies
    More analyst ratings

    $KOD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases

      PALO ALTO, Calif., May 1, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that seven scientific presentations on its research programs will be made at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting, being held from May 4-8 in Salt Lake City, Utah. "We are pleased to share new data from Kodiak's research and development efforts at this year's ARVO meeting. This body of work further highlights the power and versatility of Kodiak's ABC® (Antibody Biopolymer Conjugate) platform for

      5/1/25 11:43:00 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

      PALO ALTO, Calif., March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2024. "In September of 2024 we hosted an Investor R&D Day in New York," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "The Investor R&D Day webcast and presentation featured scientific, clinical and commercial perspectives and included key retina opinion leaders. It was an important snapshot of where we stood at that time, and where we were going – we called it Kodiak 2.0. Six months later, we are well on track." "It is remarkable that after twenty years of anti-V

      3/27/25 4:01:00 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy

      Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026.GLOW2 study design mirrors GLOW1 study, which met primary endpoint and all key secondary endpoints with high statistical significancePALO ALTO, Calif., March 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with diabetic retinopathy ("DR"). "We randomized more than 250 patients into our GLOW2 Phase 3 study, exceeding our enrollment target," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak. "With its 48-week duration of treatment, all patients are expected to com

      3/10/25 4:39:00 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KOD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

      SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

      2/14/24 4:23:00 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

      SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

      1/26/24 11:49:38 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Kodiak Sciences Inc (Amendment)

      SC 13G/A - Kodiak Sciences Inc. (0001468748) (Subject)

      2/14/23 4:19:55 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KOD
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Kodiak Sciences Inc

      DEFA14A - Kodiak Sciences Inc. (0001468748) (Filer)

      4/22/25 4:12:08 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Kodiak Sciences Inc

      DEF 14A - Kodiak Sciences Inc. (0001468748) (Filer)

      4/22/25 4:06:57 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Kodiak Sciences Inc

      S-8 - Kodiak Sciences Inc. (0001468748) (Filer)

      3/27/25 4:33:37 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KOD
    Financials

    Live finance-specific insights

    See more

    $KOD
    Leadership Updates

    Live Leadership Updates

    See more

    $KOD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024

      PALO ALTO, Calif., March 26, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that it will report fourth quarter and full-year 2023 financial results on Thursday, March 28, 2024. Management will host a conference call and live webcast to discuss recent business highlights and provide a corporate update at 4:30 p.m. Eastern Time on March 28, 2024. To access the webcast, please register at https://edge.media-server.com/mmc/p/q4jdxku4/. A live audio webcast of the event will be available on the "Events and Presentatio

      3/26/24 6:15:00 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

      PALO ALTO, Calif., Feb. 23, 2022 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b/3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel antibody biopolymer conjugate, in treatment-naïve subjects with neovascular (wet) age-related macular degeneration. The trial randomized 559 participants, approximately 80% of whom were enrolled in the United States. The study had two treatment arms: KSI-301 5mg on a flexible long-interval regimen and aflibercept 2mg on a fixed short-interval regimen. In the study, three monthly loading doses were administered to all subje

      2/23/22 6:00:00 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kodiak Sciences to Host Investor R&D Day on September 23, 2024 in New York City

      PALO ALTO, Calif., Sept. 17, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that it will host an Investor R&D Day with financial analysts and institutional investors on Monday, September 23, 2024, in New York City from 10:30 am ET to 12:30 pm ET. The event will feature presentations and roundtable discussions on Kodiak's science of durability, science of the enhanced formulation, timeline and other updates for the Company's active clinical pipeline, and the Company's expanding Antibody Biopolymer Conjugate Dr

      9/17/24 4:05:00 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pipeline Therapeutics Appoints Julie Iwashita as Vice President of Clinical Operations

      SAN DIEGO--(BUSINESS WIRE)--Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the company’s Vice President of Clinical Operations. Ms. Iwashita brings more than 30 years of experience guiding global neurology and other clinical development programs through the U.S. Food and Drug Administration (FDA) and other global health authorities. “I am delighted to welcome Julie to Pipeline Therapeutics to spearhead our clinical development efforts,” said Carmine Stengone, President & CEO of Pipeline Therapeutics. “Julie’s extensive

      12/3/20 11:00:00 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kodiak Sciences upgraded by Jefferies with a new price target

      Jefferies upgraded Kodiak Sciences from Hold to Buy and set a new price target of $20.00

      12/9/24 7:57:06 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • H.C. Wainwright initiated coverage on Kodiak Sciences with a new price target

      H.C. Wainwright initiated coverage of Kodiak Sciences with a rating of Neutral and set a new price target of $3.00

      9/5/24 7:49:18 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Goldman resumed coverage on Kodiak Sciences with a new price target

      Goldman resumed coverage of Kodiak Sciences with a rating of Sell and set a new price target of $2.00

      12/11/23 7:49:48 AM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $KOD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Officer Borgeson John A.

      4 - Kodiak Sciences Inc. (0001468748) (Issuer)

      8/7/24 4:52:43 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Chairman and CEO Perlroth Victor

      4 - Kodiak Sciences Inc. (0001468748) (Issuer)

      8/7/24 4:48:10 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Baker Bros. Advisors Lp

      4 - Kodiak Sciences Inc. (0001468748) (Issuer)

      7/2/24 4:49:54 PM ET
      $KOD
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care